MANILA (Reuters) – The Philippines will resume administering AstraZeneca (NASDAQ:)’s COVID-19 vaccine to people below 60 years of age, health officials said on Monday, ending a temporary suspension over reports of rare blood clots in younger recipients overseas,
“The benefit outweighs the risk. Only a small percentage of the population had these adverse effects for AstraZeneca,” Health Undersecretary Maria Rosario Vergeire told a regular news conference, referring to the countries where blood clots were reported.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Need Your Help Today. Your $1 can change life.